BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ferreira VL, Borba HHL, Wiens A, Pedroso MLA, Radunz VFC, Ivantes CAP, Kuniyoshi ASO, Pontarolo R. Effectiveness and tolerability of direct-acting antivirals for chronic hepatitis C patients in a Southern state of Brazil. Braz J Infect Dis 2018;22:186-92. [PMID: 29752891 DOI: 10.1016/j.bjid.2018.04.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Naguib GG, Farid A, Hassan M, Elshafie A, Shazly YE, Shaker MK, Ezzat H, Safwat E, Ahmed OA, Dabbous H, Sherief AF, Hassany M, Elserafy M, Elsayed MH. Direct-acting antiviral regimens in Egyptian patients with chronic hepatitis C virus infection: A real-world single-center experience. Arab J Gastroenterol 2021:S1687-1979(21)00043-5. [PMID: 34531135 DOI: 10.1016/j.ajg.2021.06.001] [Reference Citation Analysis]
2 Vivaldini SM, Ribeiro RA, Mosimann Júnior G, Tonini KC, Pereira GFM, Araújo WN. A real-life study of the positive response to DAA-based therapies for hepatitis C in Brazil. Braz J Infect Dis 2021;25:101573. [PMID: 33836175 DOI: 10.1016/j.bjid.2021.101573] [Reference Citation Analysis]
3 Silva IPL, Batista AD, Lopes EP, Filgueira NA, Carvalho BT, Santos JC, Medeiros TB, Melo CRL, Lima MS, Lima K, Lacerda C, Lacerda HR. A real-life study on the impact of direct-acting antivirals in the treatment of chronic hepatitis C in liver transplant recipients at two university centers in Northeastern Brazil. Rev Inst Med Trop Sao Paulo 2021;63:e6. [PMID: 33533809 DOI: 10.1590/S1678-9946202163006] [Reference Citation Analysis]
4 Peribañez-Gonzalez M, Cheinquer H, Rodrigues L, Lima MP, Álvares-da-Silva MR, Madruga J, Parise ER, Pessoa MG, Furtado J, Villanova M, Ferreira A, Mazzoleni F, Nascimento E, Silva GF, Fredrick L, Krishnan P, Burroughs M, Reuter T. Efficacy and safety of glecaprevir/pibrentasvir in treatment-naïve adults with chronic hepatitis C virus genotypes 1-6 in Brazil. Ann Hepatol 2021;20:100257. [PMID: 32949786 DOI: 10.1016/j.aohep.2020.09.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Ridruejo E, Piñero F, Mendizabal M, Cheinquer H, Wolff FH, Anders M, Reggiardo V, Ameigeiras B, Palazzo A, Alonso C, Schinoni MI, Zuain MGV, Tanno F, Figueroa S, Santos L, Peralta M, Soza A, Vistarini C, Adrover R, Fernández N, Perez D, Hernández N, Estepo C, Bruno A, Descalzi V, Sixto M, Borzi S, Cocozzella D, Zerega A, Araujo A, Varón A, Silva M; Latin American Liver Research Educational and Awareness Network (LALREAN). Decompensated cirrhosis and liver transplantation negatively impact in DAA treatment response: Real‐world experience from HCV‐LALREAN cohort. J Med Virol 2020;92:3545-55. [DOI: 10.1002/jmv.26383] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
6 Castro Filho EC, Piedade J, Castro R, Luz PM, Fernandes F, Grinsztejn B, Veloso VG, Pereira GH, Perazzo H. Effectiveness of direct-acting agents for chronic hepatitis C treatment in South America: A systematic review and meta-analysis. J Viral Hepat 2020;27:1396-407. [PMID: 32706518 DOI: 10.1111/jvh.13364] [Reference Citation Analysis]
7 Schwambach KH, Farias MR, Neto GB, Blatt CR. Cost and Effectiveness of the Treatment of Chronic Hepatitis C in Brazil: Real-World Data. Value Health Reg Issues 2020;23:49-54. [PMID: 32702649 DOI: 10.1016/j.vhri.2020.05.002] [Reference Citation Analysis]
8 Ferreira VL, Leonart LP, Pedroso MLA, Pontarolo R. Cost-utility analysis of interferon-free treatments for patients with early-stage genotype 1 hepatitis C virus in Brazil. Rev Soc Bras Med Trop 2020;53:e20190594. [PMID: 32578707 DOI: 10.1590/0037-8682-0594-2019] [Reference Citation Analysis]
9 Mushtaq S, Mansoor A, Umar M, Khan A, Siddiqi S, Manzoor S. Direct-acting antiviral agents in the treatment of chronic hepatitis C-Real-life experience from clinical practices in Pakistan. J Med Virol 2020. [PMID: 32129507 DOI: 10.1002/jmv.25745] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
10 Torres AD, Sparvoli JMH, Sparvoli AC, Gonçalves CV. SUSTAINED VIROLOGIC RESPONSE RATE IN CHRONIC HEPATITIS C PATIENTS THROUGH DIRECT-ACTING ANTIVIRALS THERAPY. Arq Gastroenterol 2019;56:394-8. [PMID: 31800735 DOI: 10.1590/S0004-2803.201900000-79] [Reference Citation Analysis]
11 Cursino CN, Monteiro PGO, Duarte GDS, Vieira TBQ, Crisante VC, Giordani F, Xavier AR, de Almeida RMVR, Calil-Elias S. Predictors of adverse drug reactions associated with ribavirin in direct-acting antiviral therapies for chronic hepatitis C. Pharmacoepidemiol Drug Saf 2019;28:1601-8. [PMID: 31692182 DOI: 10.1002/pds.4904] [Reference Citation Analysis]
12 Fernandes FF, Piedade J, Guimaraes L, Nunes EP, Chaves U, Goldenzon RV, Cardoso SW, Duarte J, Grinsztejn B, Veloso VG, Pereira G, Perazzo H. Effectiveness of direct-acting agents for hepatitis C and liver stiffness changing after sustained virological response. J Gastroenterol Hepatol. 2019;34:2187-2195. [PMID: 31062880 DOI: 10.1111/jgh.14707] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
13 Ridruejo E, Cheinquer H, Marciano S, Mendizabal M, Piñero F, Wolff FH, de Araujo A, Coelho Borges S, Kliemann D, Fleck A, de Maman Í Jr, Nader LA, Garrastazul P, Bermúdez C, Haddad L, Gadano A, Silva M. B.A.R.C.O.S. (Brazilian Argentine Hepatitis C Collaborative Observational Study): Effectiveness and clinical outcomes of HCV treatment with daclatasvir and sofosbuvir with or without ribavirin. J Viral Hepat 2019;26:1200-9. [PMID: 31141239 DOI: 10.1111/jvh.13148] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
14 Butt Z, Shah SMA. Daclatasvir plus Sofosbuvir with or without ribavirin in patients with chronic Hepatitis C genotype 3a in Pakistani population - A real world experience. Pak J Med Sci 2019;35:409-13. [PMID: 31086524 DOI: 10.12669/pjms.35.2.637] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
15 Siqueira FM, Ferreira VL, Borba HHL, Pontarolo R. Quality of life of Brazilian chronic hepatitis C patients treated with interferon-free therapies. Rev Inst Med Trop Sao Paulo. 2018;60:e72. [PMID: 30462795 DOI: 10.1590/s1678-9946201860072] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]